From the Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.
D000328:Adult; D000881:Anthrax / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis; D001408:Bacillus anthracis / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D023482:Bioterrorism; D002648:Child; D002939:Ciprofloxacin / Q000627:therapeutic use; D004219:District of Columbia / Q000453:epidemiology; D004318:Doxycycline / Q000627:therapeutic use; D005260:Female; D005431:Florida / Q000453:epidemiology; D006077:Government Agencies; D006801:Humans; D008297:Male; D008396:Maryland / Q000453:epidemiology; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009515:New Jersey / Q000453:epidemiology; D009518:New York / Q000453:epidemiology; D016273:Occupational Exposure / Q000517:prevention & control; D011177:Postal Service; D015980:Public Health Practice; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D017192:Skin Diseases, Bacterial / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D013171:Spores, Bacterial / Q000302:isolation & purification*; D014481:United States / Q000453:epidemiology; D014768:Virginia / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D004318:Doxycycline